25 Sep, 2017 New Pre-Clinical Data on “Enhanced Stabilization Chemistry Plus” (ESC+) GalNAc-siRNA Conjugate Platform

We and our collaborators presented new pre-clinical data highlighting our next generation “Enhanced Stabilization Chemistry Plus” (ESC+) GalNAc-siRNA conjugate platform, and additional data demonstrating our leadership in RNAi technologies, at the 13th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held September 24 – 27, 2017 in Bordeaux, France.

Brown et al. – “Mechanistic Insights and Progress on the GalNAc-siRNA Platform for Targeted Delivery of RNAi Therapeutics to the Liver”

Jadhav et al. – “REVERSIR^TM Platform for Rapid and Potent Reversal of RNAi-Mediated Silencing Activity”

Knight et al. – “Investigational RNAi Mediated Oxalate Reduction Therapy”

Maier et al. – “Impact of Enhanced Metabolic Stability on In Vivo Performance of GalNAc-siRNA Conjugates”

Milstein et al. – “Preclinical Development of an RNAi Therapeutic Drug Candidate Targeting Hepatitis B Virus”

Schlegel et al. – “Improved Specificity and Therapeutic Index with ESC+ siRNA Conjugates Utilizing Seed-Pairing Destabilization via Novel Chemical Modifications”

Schlegel et al. – “Impact of Glycol Nucleic Acid (GNA) on siRNA Structure and Function”

(more…)

07 Sep, 2017 2017 Summer RNAi Roundtable Series

We hosted a series of online “RNAi Roundtables” in August and September, at which Alnylam scientists, clinical collaborators, and patients or patient advocates reviewed recent progress in many of the company’s late-stage pipeline programs and discussed the related disease areas.

(more…)

28 Aug, 2017 New Positive One-Year Data from ORION-1 Phase 2 Study of Inclisiran, in Development for Hypercholesterolemia

Alnylam and The Medicines Company reported new, one-year data from the ORION-1 Phase 2 study of inclisiran, an investigational RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia, at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, Spain.

Read the press release

View the presentation

(more…)